Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗

Topics Earnings

February 14, 2026

Chime Financial delivers digital-first, fee-free banking solutions for U.S. consumers seeking accessible, low-cost financial services.

Via The Motley Fool

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗

February 11, 2026

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Bonds

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗

February 11, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

February 11, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per...

Royalty Pharma Reports Q4 and Full Year 2025 Results

February 11, 2026

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect.

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Topics World Trade

3 Mid-Cap Stocks We Keep Off Our Radar

February 05, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

3 Profitable Stocks with Open Questions

January 20, 2026

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

January 20, 2026

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Royalty Pharma Announces Dividend Increase

January 09, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Topics Artificial Intelligence Intellectual Property

3 Overrated Stocks We Steer Clear Of

December 31, 2025

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

December 29, 2025

Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over...

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

Topics Stocks

December 16, 2025

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

What's going on in today's after hours session ↗

December 08, 2025

Via Chartmill

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗

December 06, 2025

Royalty Pharma (RPRX) shows a strong technical breakout setup with a perfect 10/10 trend score and a 9/10 formation score, signaling a potential upward move.

Via Chartmill

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

December 04, 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Denali Therapeutics Inc.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

3 Mid-Cap Stocks That Concern Us

December 03, 2025

Royalty Pharma to Present at Upcoming Investor Conferences

November 26, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

3 Value Stocks with Warning Signs

November 17, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Topics Supply Chain

3 Low-Volatility Stocks We Find Risky

November 16, 2025

Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025